Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma.

ABSTRACT:

Background

Multiple myeloma is usually fatal due to serial relapses that become progressively refractory to therapy. CD19 is typically absent on the dominant multiple myeloma cell population but may be present on minor subsets with unique myeloma-propagating properties. To target myeloma-propagating cells, we clinically evaluated autologous T cells transduced with a chimeric antigen receptor (CAR) against CD19 (CTL019).

Methods

Subjects received CTL019 following salvage high-dose melphalan and autologous stem cell transplantation (ASCT). All subjects had relapsed/refractory multiple myeloma and had previously undergone ASCT with less than 1 year progression-free survival (PFS).

Results

ASCT + CTL019 was safe and feasible, with most toxicity attributable to ASCT and no

SUBMITTER: Garfall AL 

PROVIDER: S-EPMC5931130 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature